- Home
- IAC vs CRSP Comparison
IAC vs CRSP Comparison
Compare IAC & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IAC
- CRSP
- Stock Information
- Founded
- IAC N/A
- CRSP 2013
- Country
- IAC United States
- CRSP Switzerland
- Employees
- IAC N/A
- CRSP N/A
- Industry
- IAC Computer Software: Programming Data Processing
- CRSP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IAC Technology
- CRSP Health Care
- Exchange
- IAC Nasdaq
- CRSP Nasdaq
- Market Cap
- IAC 4.5B
- CRSP 4.0B
- IPO Year
- IAC 1992
- CRSP 2016
- Fundamental
- Price
- IAC $48.47
- CRSP $47.88
- Analyst Decision
- IAC Strong Buy
- CRSP Buy
- Analyst Count
- IAC 11
- CRSP 19
- Target Price
- IAC $69.91
- CRSP $73.69
- AVG Volume (30 Days)
- IAC 803.8K
- CRSP 1.9M
- Earning Date
- IAC 11-11-2024
- CRSP 11-05-2024
- Dividend Yield
- IAC N/A
- CRSP N/A
- EPS Growth
- IAC N/A
- CRSP N/A
- EPS
- IAC N/A
- CRSP N/A
- Revenue
- IAC $3,875,960,000.00
- CRSP $202,829,000.00
- Revenue This Year
- IAC N/A
- CRSP N/A
- Revenue Next Year
- IAC $1.08
- CRSP $526.27
- P/E Ratio
- IAC N/A
- CRSP N/A
- Revenue Growth
- IAC N/A
- CRSP 19.31
- 52 Week Low
- IAC $43.51
- CRSP $43.42
- 52 Week High
- IAC $58.29
- CRSP $91.10
- Technical
- Relative Strength Index (RSI)
- IAC 43.72
- CRSP 48.07
- Support Level
- IAC $46.70
- CRSP $45.51
- Resistance Level
- IAC $55.16
- CRSP $47.91
- Average True Range (ATR)
- IAC 1.80
- CRSP 2.54
- MACD
- IAC -0.21
- CRSP -0.45
- Stochastic Oscillator
- IAC 27.12
- CRSP 17.48
About IAC IAC Inc.
IAC is an internet media company with segments that include Angi (33% of total revenue), Dotdash Meredith (39%), search (14%), and emerging and other (14%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.
About CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for to treat Type 1 diabetes.